1. [Glucocorticoid-induced osteoporosis-Focus treatment (part 2)].
- Author
-
Oelzner P, Eidner T, and Pfeil A
- Subjects
- Diphosphonates therapeutic use, Glucocorticoids adverse effects, Humans, Teriparatide adverse effects, Bone Density Conservation Agents adverse effects, Osteoporosis chemically induced, Osteoporosis drug therapy, Osteoporosis prevention & control, Osteoporotic Fractures chemically induced, Osteoporotic Fractures prevention & control
- Abstract
The following substances are approved for the treatment of glucocorticoid-induced osteoporosis: the oral bisphosphonates alendronate and risedronate, the intravenous bisphosphonate zoledronate, the RANKL antibody denosumab as antiresorptive substances and teriparatide as osteoanabolic substance. In comparison to placebo a reduction of vertebral fractures is proven for all mentioned substances. Thereby, teriparatide is more effective than alendronate and risedronate with respect to the reduction of vertebral fractures. The severity of osteoporosis, especially the presence of osteoporotic fractures, the approach of treatment (preventive or curative) and contraindications are factors that are important for the differentiated application of the mentioned substances. Furthermore, it must be noted that the effect of osteoanabolic treatment must be stabilized by a subsequent antiresorptive treatment and that after termination of antiresorptive treatment with denosumab a temporary bisphosphonate treatment is required to prevent a rebound phenomenon., (© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF